NYSE · BHVN
Biohaven Ltd.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for BHVN has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.40 | $1.91 | $-0.85 | 8 |
| Mar 2027 | $-0.82 | $-0.75 | $-0.87 | 3 |
| Jun 2027 | $-0.82 | $-0.78 | $-0.87 | 3 |
| Sep 2027 | $-0.46 | $0.22 | $-0.83 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest · The Motley Fool- Zacks · Oct 29, 8:55 AM EDTWall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 43.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- RTTNews · Oct 26, 11:09 AM EDTBiohaven's BHV-1420 Targets PLA2R Autoantibodies In Membranous Nephropathy(RTTNews) – Biohaven Ltd. (BHVN) presented preclinical data for BHV-1420, an investigational drug designed to selectively remove the autoantibodies that drive membranous nephropathy, at the American Society of Nephrology's Kidney Week 2026.
- BNK Invest · Oct 23, 10:39 AM EDTMarch 2027 Options Now Available For Biohaven (BHVN)Investors in Biohaven Ltd (Symbol: BHVN) saw new options begin trading today, for the March 2027 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 147 days until expiration the newly trading contracts repres
- RTTNews · Oct 22, 3:29 PM EDTBiotech Stocks Rally: BHVN Jumps 31%, KRRO Climbs 25%, ATNM And VCRE Gain(RTTNews) – Shares of several biotech companies moved higher following corporate and clinical developments. Biohaven gained after the FDA accepted its resubmitted drug application for spinocerebellar ataxia, Korro Bio reported positive preclinical results for its AATD candidate,
- RTTNews · Oct 22, 7:58 AM EDTBiohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock Up(RTTNews) – Biohaven Ltd. (BHVN) announced that the U.S. FDA has accepted for review the company's resubmitted New Drug Application (NDA) for Vyglxia (troriluzole) as a treatment for spinocerebellar ataxia, a rare neurodegenerative disorder that affects coordination, balance, and
- RTTNews · Oct 8, 4:31 AM EDTBiohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets(RTTNews) – Biohaven Ltd. (BHVN) has entered into a strategic licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. under which Ono will obtain exclusive rights to develop and commercialize Biohaven's MoDE pan-IgG degrader portfolio in Japan, South Korea, Taiwan
- RTTNews · Aug 28, 10:42 AM EDTWeekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal(RTTNews) – This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations, and mixed clinical trial readouts.
- The Motley Fool · Aug 28, 3:32 AM EDTWhy Biohaven Stock Was Rocking the Market This WeekIts partner is South Korean peer SK Biopharmaceuticals.
- Zacks · Aug 27, 9:42 AM EDTBHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy ProgramBiohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
- RTTNews · Aug 26, 4:30 AM EDTBiohaven And SK Biopharmaceuticals Enter Strategic Global Licensing Agreement; Stock Up(RTTNews) – Biohaven Ltd. (BHVN) and SK Biopharmaceuticals Co., Ltd. announced a global licensing and collaboration agreement for Biohaven's Kv7 ion channel platform, led by Opakalim (BHV-7000), a next-generation candidate in development for epilepsy.
- RTTNews · Aug 26, 3:33 AM EDTBiohaven Gains As SK Biopharma Licenses Kv7 Epilepsy Platform In Global Deal(RTTNews) – Biohaven Ltd. (BHVN), a biopharmaceutical company, on Wednesday announced a global licensing agreement with SK Biopharmaceuticals Co., Ltd. (326030.KS).
- RTTNews · Aug 11, 4:10 PM EDTBiohaven Posts Wider Q2 Loss; To Report Phase 2/3 Data From Epilepsy Trial In H2 '26(RTTNews) – Biohaven Ltd. (BHVN), a biopharmaceutical company, on Monday posted second quarter earnings, recording a narrower net loss due to decreased operating expenses.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Biohaven Ltd. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.